Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide. On March 5, 2019, the nasal spray drug, esketamine, also known as Spravato (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression.
...
Esketamine is indicated in combination with an oral antidepressant for the treatment of treatment-resistant depression in adults. It is also indicated for the treatment of depressive symptoms in adults with major depressive disorder experiencing acute suicidal ideation or behaviour.
Beijing Tiantan Hospital, Bejing, Beijing, China
First Medical center of Chinese PLA General Hospital, Beijing, Beijing, China
Peking University First Hospital, Beijing, Beijing, China
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
Zhejiang cancer hospital, Hangzhou, Zhejiang, China
Beijing Tian Tan Hospital, Beijing, China
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
The Royal Ottawa Mental Health Centre, Ottawa, Ontario, Canada
The Second People's Hospital of Hefei, Hefei, Anhui, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.